318
Views
5
CrossRef citations to date
0
Altmetric
Research Articles

QSAR studies on the human sirtuin 2 inhibition by non-covalent 7,5,2-anilinobenzamide derivatives

, , , , , & show all
Pages 354-363 | Received 26 Jun 2018, Accepted 16 Jan 2019, Published online: 21 Feb 2019
 

Abstract

Sirtuin 2 is a key enzyme in gene expression regulation that is often associated with tumor proliferation control and therefore is a relevant anticancer drug target. Anilinobenzamide derivatives have been discussed as selective sirtuin 2 inhibitors and can be developed further. In the present study, hologram and three-dimensional quantitative structure–activity relationship (HQSAR and 3D-QSAR) analyses were employed for determining structural contributions of a compound series containing human sirtuin-2-selective inhibitors that were then correlated with structural data from the literature. The final QSAR models were robust and predictive according to statistical validation (q2 and r2pred values higher than 0.85 and 0.75, respectively) and could be employed further to generate fragment contribution and contour maps. 3D-QSAR models together with information about the chemical properties of sirtuin 2 inhibitors can be useful for designing novel bioactive ligands.

Communicated by Ramaswamy H. Sarma

Acknowledgments

The authors thank OpenEye Scientific Software for ROCS, OMEGA and QUACPAC academic licenses.

Author contribution

GMF, TK and VGM contributed to the experiment design. GMF, JGM, TK and VGM contributed to dataset organization. GMF and VGM contributed to model inference and validation. TK, GHT, AG, FSE and VGM contributed to discussion and writing of the paper.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was supported by the CNPq [grant number 312009/2014-3], [grant number 456984/2014-3], [grant number 310232/2017-1], [grant number436791/2018-8]; FAPESP [grant number 2017/25543-8]; GlaxoSmithKline; and CAPES.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.